NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01367002,Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,https://clinicaltrials.gov/study/NCT01367002,,COMPLETED,The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine Serous Papillary Carcinoma (USPC) patients overexpressing Her2/neu at 3+ level by immunohistochemistry (IHC)or positive by fluorescence in situ hybridization (FISH).,YES,Endometrial Cancer,DRUG: Carboplatin/Paclitaxel|DRUG: Trastuzumab,"Progression Free Survival Differences Between Treatment Arms., Progression free survival differences between treatment arms., 6 years","To Assess the Safety Profile of Trastuzumab in USPC Patients by CTCAE v4.0, To assess the safety profile of trastuzumab in USPC patients by CTCAE v4.0. Presented are counts of those that experience any Serious Adverse Events or All Other Adverse Events., 6 years|To Assess Objective Response Rate (ORR), To assess objective response rate (ORR), 6 years|To Assess Overall Survival (OS), To assess overall survival (OS), presented are the number of participants that survived through the duration of the study period., 6 years",,Yale University,"Genentech, Inc.",FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1012007786,2011-06,2022-06-30,2022-06-30,2011-06-06,2023-04-18,2023-05-17,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, 85013, United States|University of Arizona Cancer Center, Tucson, Arizona, 85724, United States|John Muir Clinical Research Center, Concord, California, 94520, United States|Women's Cancer Research Foundation, Newport Beach, California, 92663, United States|Penrose St. Francis Hospital, Colorado Springs, Colorado, 80907, United States|Danbury Hospital, Danbury, Connecticut, 06810, United States|University of Connecticut Health Center, Farmington, Connecticut, 06030, United States|The Hospital of Central Connecticut, New Britain, Connecticut, 06050, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, 06510, United States|The University of Chicago Medicine, Chicago, Illinois, 60637, United States|Greater Baltimore Medical Center, Baltimore, Maryland, 21204, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, 20889-5600, United States|Holy Cross Hospital, Silver Spring, Maryland, 20910, United States|University of Maryland Medical Center, Silver Spring, Maryland, 20910, United States|Jersey Shore University Medical Center, Neptune, New Jersey, 07753, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|Duke University School of Medicine, Durham, North Carolina, 27710, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|The Ohio State University, Hilliard, Ohio, 43026, United States|University of Virginia, Charlottesville, Virginia, 22908, United States","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/02/NCT01367002/Prot_SAP_000.pdf"
